Podium to Practice: Chicago 2026 – GU: KEYNOTE-564 trial & RAMPART
OR
Studies / Trials Discussed
4502 – ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
LBA4511 – Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
4502 – ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
LBA4511 – Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.